Vergote IB - Search Results

1

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma.

Kristensen GB, Baekelandt M, Vergote IB, Tropé C. Kristensen GB, et al. Among authors: vergote ib. Eur J Cancer. 1995 Oct;31A(11):1778-80. doi: 10.1016/0959-8049(95)00274-m. Eur J Cancer. 1995. PMID: 8541099 Clinical Trial.

2

Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look.

Ramm K, Vergote IB, Kaern J, Tropé CG. Ramm K, et al. Among authors: vergote ib. Gynecol Oncol. 1992 Aug;46(2):203-7. doi: 10.1016/0090-8258(92)90256-i. Gynecol Oncol. 1992. PMID: 1379961

3

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.

Vergote I, Himmelmann A, Frankendal B, Scheistrøen M, Vlachos K, Tropé C. Vergote I, et al. Gynecol Oncol. 1992 Dec;47(3):282-6. doi: 10.1016/0090-8258(92)90127-5. Gynecol Oncol. 1992. PMID: 1473738

4

Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice.

Vergote I, Larsen RH, De Vos L, Winderen M, Ellingsen T, Bjørgum J, Hoff P, Aas M, Tropé C, Nustad K. Vergote I, et al. Gynecol Oncol. 1992 Dec;47(3):358-65. doi: 10.1016/0090-8258(92)90140-e. Gynecol Oncol. 1992. PMID: 1473750

5

Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.

Vergote I, Larsen RH, de Vos L, Nesland JM, Bruland O, Bjørgum J, Alstad J, Tropé C, Nustad K. Vergote I, et al. Gynecol Oncol. 1992 Dec;47(3):366-72. doi: 10.1016/0090-8258(92)90141-5. Gynecol Oncol. 1992. PMID: 1473751

6

CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma.

Vergote IB, Abeler VM, Børmer OP, Stigbrand T, Tropé C, Nustad K. Vergote IB, et al. Tumour Biol. 1992;13(3):168-74. doi: 10.1159/000217761. Tumour Biol. 1992. PMID: 1626181

7

Intraperitoneal antineoplastic agents in the management of ovarian cancer.

Tropé C, Kaern J, Vergote I. Tropé C, et al. Eur J Surg Suppl. 1991 May;(561):83-6. Eur J Surg Suppl. 1991. PMID: 1720054 Review. No abstract available.

8

Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer.

Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjørstad KE, Tropé CG. Vergote IB, et al. Among authors: vergote de vos ln. Cancer. 1992 Feb 1;69(3):741-9. doi: 10.1002/1097-0142(19920201)69:3<741::aid-cncr2820690322>3.0.co;2-g. Cancer. 1992. PMID: 1730124 Clinical Trial.

9

Management of malignant ovarian immature teratoma. Role of adriamycin.

Vergote IB, Abeler VM, Kjørstad KE, Tropé C. Vergote IB, et al. Cancer. 1990 Sep 1;66(5):882-6. doi: 10.1002/1097-0142(19900901)66:5<882::aid-cncr2820660512>3.0.co;2-8. Cancer. 1990. PMID: 2201432 Review.

10

[A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer].

Kaern J, Tropé C, Kjørstad KE, Nordal R, Sundfør K, Vergote I, Vossli S, Abeler V, Sandvei R. Kaern J, et al. Tidsskr Nor Laegeforen. 1990 Sep 10;110(21):2759-62. Tidsskr Nor Laegeforen. 1990. PMID: 2219049 Norwegian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters